玻璃体视网膜淋巴瘤是一种具有较高致死率的恶性肿瘤。罹患率较低，缺乏指导治疗的医学证据。本研究描述了最近被诊断和治疗的患者队列的临床展现、诊断测试和首次治疗方法。临床登记的观察性研究。诊断为玻璃体视网膜淋巴瘤的48名女性及32名男性患者（年龄为32至91岁，中位数为64岁）。国际眼科医生网络通过电子平台报告了2020年1月1日至2022年12月31日期间患有玻璃体视网膜淋巴瘤的患者的临床特征和管理情况。首次就诊时的视觉力（LogMAR）；诊断依据；首次治疗。玻璃体视网膜淋巴瘤在65%的患者（N=52）的首次就诊时是双眼成病，78%的患者（N=62）首次出现淋巴瘤部位。在首诊时有127只眼出现淋巴瘤，其中玻璃体受累89%（N=113），且是唯一受累眼组织的40%（N=51）；视网膜受累46%（N=58），且是唯一受累眼组织的9%（N=11）。最差视力眼的中位数LogMAR为0.50。80%的患者（N=64）通过眼部标本诊断出淋巴瘤，通常是玻璃体（N=57，占64患者的89%），20%的患者（N=16）通过其他临床信息诊断。92%的患者（64名中的59名）进行了细胞学研究，其中最常见的是细胞学检查。21名患者（64名中的33%）进行了肿瘤基因分析，13名患者（64名中的20%）进行了细胞因子测定。76位患者（95%）在诊断后的6个月内开始接受治疗，包括眼部（48%，76名中的38名）、眼部外（21%，76名中的17名）和眼部外加眼部联合（26%，76名中的21名）治疗方法。玻璃体内甲氨蝶呤是最常见的眼部治疗方法（83只眼中的87只，占95%）。通过收集自2020年以来诊断为玻璃体视网膜淋巴瘤的80名患者的数据，我们表明视力障碍普遍存在，并且常见的治疗方法包括通过细胞学测试进行诊断和使用玻璃体内化疗进行治疗。版权所有 © 2023 Elsevier Inc.

Vitreoretinal lymphoma is a malignancy with high mortality. Incidence is rare, and there is a lack of medical evidence to direct management. This work describes presentation, diagnostic testing and first treatment approaches in a recently diagnosed and treated patient cohort.Clinical registry-based observational study.48 women and 32 men (32 to 91 years, median of 64 years) diagnosed with vitreoretinal lymphoma.An international network of ophthalmologists reported clinical features and management of patients presenting with vitreoretinal lymphoma between January 1, 2020 and December 31, 2022 via an electronic platform.Visual acuity at presentation (LogMAR); basis for diagnosis; first treatment.Vitreoretinal lymphoma was bilateral at presentation in 65% of patients (N = 52) and an initial site of lymphoma in 78% (N = 62). In 127 eyes with lymphoma at presentation, vitreous was involved in 89% (N = 113) and the only involved eye tissue in 40% (N = 51), and retina was involved in 46% (N = 58) and the only involved eye tissue in 9% (N = 11). Median LogMAR visual acuity of the worse-seeing eye was 0.50. The lymphoma was diagnosed from ocular specimens in 80% (N = 64), usually vitreous (N = 57, 89% of 64 patients), and on other clinical information in 20% (N = 16). Cellular studies were performed in 92% (59 of 64 patients), most often cytology. Tumor gene analysis was used in 21 patients (33% of 64) and cytokine assays were used in 13 patients (20% of 64). For 76 patients (95%), treatment was initiated within 6 months of diagnosis and included ocular (48%, N = 38 of 76 patients), extraocular (21%, N = 17 of 76), and ocular plus extraocular (26%, N = 21 of 76) approaches. Intravitreal methotrexate was the most common ocular treatment (N = 83 of 87 eyes, 95%).Using data collected from 80 patients diagnosed with vitreoretinal lymphoma since 2020, we show that visual impairment is common, and that management commonly involves diagnosis by cellular tests and treatment with intravitreal chemotherapy.Copyright © 2023. Published by Elsevier Inc.